S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

$28.50
+2.85 (+11.11%)
(As of 03/27/2024 ET)
Today's Range
$25.62
$29.36
50-Day Range
$17.68
$28.50
52-Week Range
$9.41
$29.36
Volume
922,344 shs
Average Volume
118,377 shs
Market Capitalization
$788.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33

Aerovate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
73.1% Upside
$49.33 Price Target
Short Interest
Healthy
5.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Aerovate Therapeutics in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$701,281 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.74) to ($2.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

639th out of 939 stocks

Pharmaceutical Preparations Industry

292nd out of 422 stocks

AVTE stock logo

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Stock Price History

AVTE Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Recap: Aerovate Therapeutics Q4 Earnings
Aerovate Therapeutics Inc AVTE
BTIG Keeps Their Buy Rating on Aerovate Therapeutics (AVTE)
See More Headlines
Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
3/27/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.33
High Stock Price Target
$65.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+73.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.19 per share

Miscellaneous

Free Float
22,329,000
Market Cap
$788.60 million
Optionable
Not Optionable
Beta
1.18
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Timothy P. Noyes M.B.A. (Age 62)
    CEO & Director
    Comp: $703.8k
  • Mr. George A. Eldridge (Age 61)
    CFO & Treasurer
    Comp: $533.89k
  • Dr. Marinus Verwijs Ph.D. (Age 48)
    Chief Technical Officer
    Comp: $439.88k
  • Dr. Benjamin T. Dake Ph.D. (Age 48)
    Founder, President, COO & Secretary
    Comp: $435.5k
  • Dr. Ralph W. Niven M.B.A. (Age 64)
    M.R, Ph.D., Pharm.S, Chief Scientific Officer
    Comp: $372.33k
  • Mr. Hunter Gillies M.D. (Age 58)
    Chief Medical Officer
    Comp: $512.74k
  • Mr. Timothy J. Pigot (Age 53)
    Chief Commercial Officer
  • Ms. Donna Dea
    Head of Regulatory Affairs
  • Ms. Susan Fischer
    Senior Vice President of Development Operations
  • Mr. Stephen K. Yu
    Senior Vice President of Quality

AVTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVTE shares.
View AVTE analyst ratings
or view top-rated stocks.

What is Aerovate Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they predict the company's stock price to reach $49.33 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for AVTE
or view top-rated stocks among Wall Street analysts.

How have AVTE shares performed in 2024?

Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE stock has increased by 25.9% and is now trading at $28.50.
View the best growth stocks for 2024 here
.

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 903,700 shares, a drop of 10.5% from the February 29th total of 1,010,000 shares. Based on an average trading volume of 102,500 shares, the short-interest ratio is presently 8.8 days. Currently, 5.3% of the company's shares are sold short.
View Aerovate Therapeutics' Short Interest
.

When is Aerovate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our AVTE earnings forecast
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced its quarterly earnings data on Sunday, November, 14th. The company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26).

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Who are Aerovate Therapeutics' major shareholders?

Aerovate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (3.75%), Vanguard Group Inc. (2.27%), Vanguard Group Inc. (2.27%), Point72 Asset Management L.P. (1.60%), Octagon Capital Advisors LP (1.46%) and Vestal Point Capital LP (1.45%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes.
View institutional ownership trends
.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners